Current reports
6-K
Current report (foreign)
21 May 24
6-K
Current report (foreign)
1 May 24
6-K
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBIDTA of over NIS 50 million
1 Apr 24
6-K
InterCure Provides an Update Regarding Nir Oz Facility
13 Feb 24
6-K
Current report (foreign)
13 Feb 24
6-K
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
31 Jan 24
6-K
Current report (foreign)
14 Dec 23
6-K
Annual General Meeting of Shareholders to Be
8 Nov 23
6-K
Current report (foreign)
31 Oct 23
6-K
InterCure Provides an Update Regarding the Security Situation in Israel
17 Oct 23
Registration and prospectus
POS AM
Prospectus update (post-effective amendment)
23 Jun 22
424B3
Prospectus supplement
4 Oct 21
F-1/A
Registration statement (foreign) (amended)
23 Sep 21
F-1/A
Registration statement (foreign) (amended)
9 Sep 21
20FR12B/A
Initial registration of securities (foreign private issuers) (amended)
16 Aug 21
20FR12B/A
Initial registration of securities (foreign private issuers) (amended)
3 Aug 21
F-1/A
Registration statement (foreign) (amended)
3 Aug 21
F-1
Registration statement (foreign)
15 Jul 21
20FR12B
Initial registration of securities (foreign private issuers)
14 Jul 21
DRS/A
Draft registration statement (amended)
2 Jul 21
Proxies
No filings
Other
EFFECT
Notice of effectiveness
27 Jun 22
EFFECT
Notice of effectiveness
5 Oct 21
CORRESP
Correspondence with SEC
30 Sep 21
CORRESP
Correspondence with SEC
23 Sep 21
UPLOAD
Letter from SEC
16 Sep 21
SEC STAFF
SEC staff action: Order
31 Aug 21
CERT
Certification of approval for exchange listing
30 Aug 21
CORRESP
Correspondence with SEC
27 Aug 21
CORRESP
Correspondence with SEC
2 Aug 21
UPLOAD
Letter from SEC
15 Jul 21
Ownership